A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors

A Multicenter, Open-label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors

A multicenter, open-label, phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH002 in combination with YH001 in subjects with advanced solid tumors

Study Overview

• Status: Completed
• Conditions: Advanced Solid Tumor
• Intervention / Treatment: Drug: A:YH002+YH001; Drug: B:YH002+YH001; Drug: YH002+YH001

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Orange, New South Wales, Australia, 2800
      • Orange Health Services
    • Sydney, New South Wales, Australia, 2109
      • Macquarie University Hospital
  • Victoria
    • Frankston, Victoria, Australia, 3199
      • Peninsula and South Eastern Haematology & Oncology Group
    • Malvern, Victoria, Australia, 3144
      • Cabrini Hospital Malvern
• China
  • Henan
    • Zhengzhou, Henan, China, 450008
      • Henan Tumor Hospital
  • Hubei
    • Wuhan, Hubei, China, 430022
      • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • Liaoning
    • Shenyang, Liaoning, China, 110801
      • Liaoning Cancer Hospital
  • Shanghai
    • Shanghai, Shanghai, China, 200020
      • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
  • Zhejiang
    • Hangzhou, Zhejiang, China, 310020
      • Sir Run Run Shaw Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

To be eligible for study entry patients must satisfy all of the following criteria:

1. Subjects must have the ability to understand and willingness to sign a written informed consent document.
2. Subjects must have histologically advanced or cytologically confirmed solid tumor and and must have at least 1 unidimensional measurable lesion by RECIST 1.1.
3. Subjects have progressed on after treatment with at least one standard therapy, or intolerant of the standard therapy, or no standard therapy accessible to the patients due to any reason.
4. Subjects must be age 18 to 80 years of age at the time of screening.
5. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
6. Life expectancy ≥3 months based on investigator's judgement.
7. Subjects have adequate bone marrow and other organ function at the screening visit.
8. Women of reproductive potential must have negative serum beta human chorionic gonadotropin (β -HCG) pregnancy test within 7 days of the first dosing. Women of reproductive potential are those who have not been post-menopausal for at least 12 months or who have not undergone bilateral tubal occlusion, hysterectomy, or bilateral salpingectomy.

Exclusion Criteria:

Subjects who meet any of the following criteria cannot be enrolled:

1. Subjects have another active invasive malignancy within 5 years.
2. Previous exposure to TNFR such as anti-OX40 antibodies.
3. Subjects must not have received any anticancer therapy or another investigational agent within the shorter of 4 weeks or 5 half-lives before the first dose of the study treatment(subject to the longer one).
4. Continuance of toxicities due to prior radiotherapy or chemotherapy agents that have not recovered to ≤ Grade 1 per CTCAE 5.0, except alopecia ≤ Grade 2.
5. Primary central nervous system (CNS) malignancies or symptomatic CNS metastases.
6. Subjects must not have a known or suspected history of an autoimmune disorder, including but not limited to inflammatory bowel disease, celiac disease, Wegner syndrome, Hashimoto syndrome, systemic lupus erythematosus, scleroderma, sarcoidosis, or autoimmune hepatitis, within 3 years of the first dose of study treatment.
7. Clinically uncontrolled intercurrent illness, including but not limit to an ongoing active infection, active coagulopathy, uncontrolled diabetes (blood glucose > 250 mg/dl), uncontrolled pleural and peritoneal effusion, psychiatric illness that would limit compliance with the study requirements and other serious medical illnesses requiring systemic therapies
8. Subjects must not have active infection of human immunodeficiency virus, hepatitis B, hepatitis C or Covid-19.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: YH002 in combination with YH001; Dose escalation:A traditional 3+3 dose escalation algorithm will be utilized to identify MTD and/or RP2D Dose expansion:One selected dose after the escalation stage will be expanded to enroll additional 20 subjects. The subjects will be divided into two groups：A and B.	Drug: A:YH002+YH001; YH002 on CnD1,YH001 on CnD8,Q3W; Drug: B:YH002+YH001; YH002 and YH001 on same day,Q3W; Drug: YH002+YH001; A traditional 3+3 dose escalation algorithm

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determined the maximum tolerated dose (MTD)	The safety profile of combination treatment will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0	Up to 1 year after the last dosing
Determined the recommended Phase II dose (RP2D)	The safety profile of combination treatment will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0	Up to 1 year after the last dosing

Collaborators and Investigators

• Sponsor: Eucure (Beijing) Biopharma Co., Ltd
• Investigators: Principal Investigator: Hongming Pan, Sir Run Run Shaw Hospital

Study record dates

Study Major Dates

• Study Start (Actual): February 21, 2022
• Primary Completion (Actual): July 4, 2023
• Study Completion (Actual): July 4, 2023

Study Registration Dates

• First Submitted: December 10, 2021
• First Submitted That Met QC Criteria: December 10, 2021
• First Posted (Actual): December 27, 2021

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 3, 2025
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: YH002004

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No